Company Overview
Snapshot
Founded in January 2007, VVT Medical operates with 11–50 employees and has raised a total of $2.6 million across two funding rounds, with I3 Capital Group as an investor. The company became public on the TSX Venture Exchange in July 2025.
Business overview
VVT Medical specializes in the research, development, manufacturing, and commercialization of minimally invasive, non-thermal, non-tumescent solutions for treating varicose veins. The company's core technology is the ScleroSafe platform, which enables quick, office-based procedures without the need for tumescent anesthesia or costly capital equipment. VVT Medical's solutions, including ScleroSafe with V-Block, are designed to treat severely dilated and challenging Great Saphenous Vein conditions, serving the healthcare and life sciences sectors, particularly providers in vein clinics, day care clinics, angio suites, catheterization laboratories, and hospitals.
Strategic signal
In June 2026, VVT Medical expanded its market presence by appointing Antilles Medical as its exclusive distributor in the Dominican Republic. This strategic move indicates the company's continued focus on international market penetration and broadening the reach of its ScleroSafe system, signaling potential for increased revenue and market share in new territories for investors.
Log in to access full profile ›Company Intelligence Q&A
- When did VVT Medical become a publicly traded company?
- VVT Medical Inc. announced the commencement of trading on the TSX Venture Exchange in July 2025.
- What is the ScleroSafe system?
- The ScleroSafe system is VVT Medical's flagship platform, designed for minimally invasive, non-thermal, non-tumescent treatment of varicose veins, enabling office-based procedures without tumescent anesthesia or expensive capital equipment.
- Did VVT Medical recently expand its distribution?
- In June 2026, VVT Medical expanded into the Dominican Republic by appointing Antilles Medical as its exclusive distributor.
- What was a recent clinical milestone for VVT Medical?
- In May 2026, VVT Med announced that the first patients were treated with its ScleroSafe™ System in Italy.
- Has VVT Medical received any significant orders recently?
- In November 2025, VVT Med received an order from the major US healthcare network NorthWell Health.